- 著者
-
岡田 誠治
- 出版者
- 日本サイトメトリー学会
- 雑誌
- サイトメトリーリサーチ (ISSN:09166920)
- 巻号頁・発行日
- vol.27, no.2, pp.51-56, 2017-11-25 (Released:2017-11-25)
- 参考文献数
- 22
Patient-derived xenograft (PDX) models can be created with transplantation of cancerous cells or tissues from patient’s primary tumors into immunodeficient mice. PDX technology leads to the breakthrough with the introduction of novel highly immunodeficient mice such as NOG (NOD/Scid/IL2Rγnull), NSG (NOD/Scid/IL2Rγnull), and NOJ (NOD/Scid/Jak3null) mice. As PDX has been shown to conserve human original tumor characteristics, it is now getting standard methods to evaluate the drug sensitivity, and PDX library is now established in many organization with integrated genomic signature. These PDX data base are getting powerful tool for advancing Precision Cancer Medicine.